{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).", "output": "Entities: Ketoconazole, tolterodine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "output": "Entities: ketoconazole, DETROL LA; Relationship: advise\nEntities: azole antifungals, DETROL LA; Relationship: advise\nEntities: itraconazole, DETROL LA; Relationship: advise\nEntities: miconazole, DETROL LA; Relationship: advise\nEntities: macrolide antibiotics, DETROL LA; Relationship: advise\nEntities: erythromycin, DETROL LA; Relationship: advise\nEntities: clarithromycin, DETROL LA; Relationship: advise\nEntities: cyclosporine, DETROL LA; Relationship: advise\nEntities: vinblastine, DETROL LA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.", "output": "Entities: paliperidone, centrally acting drugs; Relationship: advise\nEntities: paliperidone, alcohol; Relationship: advise\nEntities: INVEGA, centrally acting drugs; Relationship: advise\nEntities: INVEGA, alcohol; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Paliperidone may antagonize the effect of levodopa and other dopamine agonists.", "output": "Entities: Paliperidone, levodopa; Relationship: effect\nEntities: Paliperidone, dopamine agonists; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.", "output": "Entities: oxybutynin, anticholinergic drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.", "output": "Entities: DITROPAN XL, ketoconazole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "output": "Entities: antimycotic agents, oxybutynin; Relationship: mechanism\nEntities: itraconazole, oxybutynin; Relationship: mechanism\nEntities: miconazole, oxybutynin; Relationship: mechanism\nEntities: macrolide antibiotics, oxybutynin; Relationship: mechanism\nEntities: erythromycin, oxybutynin; Relationship: mechanism\nEntities: clarithromycin, oxybutynin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.", "output": "Entities: Mitotane, warfarin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.", "output": "Entities: Mitotane, coumarin-type anticoagulants; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.", "output": "Entities: vancomycin, anesthetic agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).", "output": "Entities: TRITEC, clarithromycin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.", "output": "Entities: antacid, ranitidine; Relationship: mechanism\nEntities: antacid, TRITEC; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "output": "Entities: SPIRIVA, anticholinergic; Relationship: advise\nEntities: SPIRIVA, ipratropium; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.", "output": "Entities: tigecycline, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.", "output": "Entities: antibacterial drugs, contraceptives; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "output": "Entities: Triprolidine, central nervous system depressants; Relationship: effect\nEntities: Triprolidine, alcohol; Relationship: effect\nEntities: Triprolidine, barbiturates; Relationship: effect\nEntities: Triprolidine, hypnotics; Relationship: effect\nEntities: Triprolidine, narcotic analgesics; Relationship: effect\nEntities: Triprolidine, sedatives; Relationship: effect\nEntities: Triprolidine, tranquillisers; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.", "output": "Entities: anticholinergic drugs, triprolidine; Relationship: effect\nEntities: atropine, triprolidine; Relationship: effect\nEntities: tricyclic antidepressants, triprolidine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.", "output": "Entities: Methergine, vasoconstrictors; Relationship: advise\nEntities: Methergine, ergot alkaloids; Relationship: advise\nEntities: methylergonovine maleate, vasoconstrictors; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.", "output": "Entities: trimetrexate, erythromycin; Relationship: effect\nEntities: trimetrexate, rifampin; Relationship: effect\nEntities: trimetrexate, rifabutin; Relationship: effect\nEntities: trimetrexate, ketoconazole; Relationship: effect\nEntities: trimetrexate, fluconazole; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.", "output": "Entities: cimetidine, trimetrexate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.", "output": "Entities: imidazole drugs, trimetrexate; Relationship: mechanism\nEntities: clotrimazole, trimetrexate; Relationship: mechanism\nEntities: ketoconazole, trimetrexate; Relationship: mechanism\nEntities: miconazole, trimetrexate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see", "output": "Entities: AGGRASTAT, heparin; Relationship: effect\nEntities: AGGRASTAT, aspirin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.", "output": "Entities: diphosphonate, Calcitonin (salmon); Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.", "output": "Entities: Matulane, sympathomimetic drugs; Relationship: advise\nEntities: Matulane, tricyclic antidepressant; Relationship: advise\nEntities: Matulane, amitriptyline HCl; Relationship: advise\nEntities: Matulane, imipramine HCl; Relationship: advise\nEntities: Matulane, tyramine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.", "output": "Entities: lithium, Neulasta; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.", "output": "Entities: Sirolimus, MYCAMINE; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.", "output": "Entities: Nifedipine, MYCAMINE; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.", "output": "Entities: sirolimus, MYCAMINE; Relationship: advise\nEntities: nifedipine, MYCAMINE; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.", "output": "Entities: opioids, levomepromazine; Relationship: effect\nEntities: levomepromazine, opioids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.", "output": "Entities: levomepromazine, benzodiazepines; Relationship: effect\nEntities: levomepromazine, barbiturates; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.", "output": "Entities: levomepromazine, anticholinergic drugs; Relationship: advise\nEntities: levomepromazine, tricyclic antidepressants; Relationship: advise\nEntities: levomepromazine, antiparkinsonian-agents; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.", "output": "Entities: Caffeine, levomepromazine; Relationship: effect\nEntities: ephedrine, levomepromazine; Relationship: effect\nEntities: amphetamine, levomepromazine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.", "output": "Entities: succinylcholine, nondepolarizing agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.", "output": "Entities: succinylcholine, MIVACRON; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "output": "Entities: nondepolarizing agents, antibiotics; Relationship: int\nEntities: nondepolarizing agents, aminoglycosides; Relationship: int\nEntities: nondepolarizing agents, tetracyclines; Relationship: int\nEntities: nondepolarizing agents, bacitracin; Relationship: int\nEntities: nondepolarizing agents, polymyxins; Relationship: int\nEntities: nondepolarizing agents, lincomycin; Relationship: int\nEntities: nondepolarizing agents, clindamycin; Relationship: int\nEntities: nondepolarizing agents, colistin; Relationship: int\nEntities: nondepolarizing agents, sodium colistimethate; Relationship: int\nEntities: nondepolarizing agents, magnesium; Relationship: int\nEntities: nondepolarizing agents, lithium; Relationship: int\nEntities: nondepolarizing agents, anesthetics; Relationship: int\nEntities: nondepolarizing agents, procainamide; Relationship: int\nEntities: nondepolarizing agents, quinidine; Relationship: int\nEntities: MIVACRON, antibiotics; Relationship: int\nEntities: MIVACRON, aminoglycosides; Relationship: int\nEntities: MIVACRON, tetracyclines; Relationship: int\nEntities: MIVACRON, bacitracin; Relationship: int\nEntities: MIVACRON, polymyxins; Relationship: int\nEntities: MIVACRON, lincomycin; Relationship: int\nEntities: MIVACRON, clindamycin; Relationship: int\nEntities: MIVACRON, colistin; Relationship: int\nEntities: MIVACRON, sodium colistimethate; Relationship: int\nEntities: MIVACRON, magnesium; Relationship: int\nEntities: MIVACRON, lithium; Relationship: int\nEntities: MIVACRON, anesthetics; Relationship: int\nEntities: MIVACRON, procainamide; Relationship: int\nEntities: MIVACRON, quinidine; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.", "output": "Entities: MIVACRON, contraceptives; Relationship: effect\nEntities: MIVACRON, glucocorticoids; Relationship: effect\nEntities: MIVACRON, monoamine oxidase inhibitors; Relationship: effect\nEntities: neuromuscular blocking agents, phenytoin; Relationship: effect\nEntities: neuromuscular blocking agents, carbamazepine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "output": "Entities: phenytoin, MIVACRON; Relationship: effect\nEntities: carbamazepine, MIVACRON; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.", "output": "Entities: VESIcare, ketoconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.", "output": "Entities: minoxidil, guanethidine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If at all possible guanethidine should be discontinued well before minoxidil is begun.", "output": "Entities: guanethidine, minoxidil; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.", "output": "Entities: ZAVESCA, Cerezyme; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.", "output": "Entities: Cerezyme, ZAVESCA; Relationship: advise\nEntities: imiglucerase, ZAVESCA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.", "output": "Entities: Aminoglutethimide, depo-subQ provera 104; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thiazides may decrease arterial responsiveness to norepinephrine.", "output": "Entities: Thiazides, norepinephrine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thiazide drugs may increase the responsiveness of tubocurarine.", "output": "Entities: Thiazide drugs, tubocurarine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.", "output": "Entities: Lithium, thiazides; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thiazides may add to or potentiate the action of other antihypertensive drugs.", "output": "Entities: Thiazides, antihypertensive drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.", "output": "Entities: diuretics, ACEON; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.", "output": "Entities: diuretic, perindopril; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.", "output": "Entities: diuretics, ACEON; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.", "output": "Entities: digoxin, perindopril; Relationship: mechanism\nEntities: digoxin, perindoprilat; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.", "output": "Entities: perindopril, gentamicin; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "output": "Entities: alcohol, methyprylon; Relationship: effect\nEntities: CNS depression-producing drugs, methyprylon; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Administration of valproic acid decreases oral clearance of temozolomide by about 5%.", "output": "Entities: valproic acid, temozolomide; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.", "output": "Entities: tolbutamide, teniposide; Relationship: mechanism\nEntities: sodium salicylate, teniposide; Relationship: mechanism\nEntities: sulfamethizole, teniposide; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.", "output": "Entities: methotrexate, teniposide; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.", "output": "Entities: anticoagulants, methimazole; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.", "output": "Entities: CYLERT, antiepileptic medications; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.", "output": "Entities: Furosemide, metolazone; Relationship: effect\nEntities: loop diuretics, metolazone; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.", "output": "Entities: MYKROX, antihypertensive drugs; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.", "output": "Entities: Diuretic, digitalis; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.", "output": "Entities: Diuretic, curariform drugs; Relationship: effect\nEntities: Diuretic, tubocurarine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.", "output": "Entities: Salicylates, MYKROX; Relationship: effect\nEntities: Non-Steroidal Anti-Inflammatory Drugs, MYKROX; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.", "output": "Entities: Metolazone, norepinephrine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.", "output": "Entities: Methenamine, metolazone; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;", "output": "Entities: Metolazone, anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "output": "Entities: anticholinergic drugs, amantadine; Relationship: effect\nEntities: anticholinergic drugs, antiarrhythmic agents of class I; Relationship: effect\nEntities: anticholinergic drugs, quinidine; Relationship: effect\nEntities: anticholinergic drugs, antihistamines; Relationship: effect\nEntities: anticholinergic drugs, antipsychotic agents; Relationship: effect\nEntities: anticholinergic drugs, phenothiazines; Relationship: effect\nEntities: anticholinergic drugs, benzodiazepines; Relationship: effect\nEntities: anticholinergic drugs, MAO inhibitors; Relationship: effect\nEntities: anticholinergic drugs, narcotic analgesics; Relationship: effect\nEntities: anticholinergic drugs, meperidine; Relationship: effect\nEntities: anticholinergic drugs, nitrates; Relationship: effect\nEntities: anticholinergic drugs, nitrites; Relationship: effect\nEntities: anticholinergic drugs, sympathomimetic agents; Relationship: effect\nEntities: anticholinergic drugs, tricyclic antidepressants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinergics antagonize the effects of antiglaucoma agents.", "output": "Entities: Anticholinergics, antiglaucoma agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.", "output": "Entities: Anticholinergic drugs, corticosteroids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;", "output": "Entities: Anticholinergic agents, digoxin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.", "output": "Entities: Anticholinergic drugs, metoclopramide; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.", "output": "Entities: antacids, anticholinergic agents; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.", "output": "Entities: Ropivacaine, anesthetics; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.", "output": "Entities: ropivacaine, fluvoxamine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.", "output": "Entities: fluvoxamine, Ropivacaine; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "output": "Entities: ketoconazole, ropivacaine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.", "output": "Entities: sulfamethoxazole, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.", "output": "Entities: Sulfamethoxazole, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.", "output": "Entities: sulfamethoxazole, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.", "output": "Entities: Sulfonamides, methotrexate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.", "output": "Entities: PURINETHOL, TABLOID; Relationship: effect\nEntities: PURINETHOL, Thioguanine; Relationship: effect\nEntities: mercaptopurine, TABLOID; Relationship: effect\nEntities: mercaptopurine, Thioguanine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.", "output": "Entities: aminosalicylate derivatives, thioguanine; Relationship: mechanism\nEntities: olsalazine, thioguanine; Relationship: mechanism\nEntities: mesalazine, thioguanine; Relationship: mechanism\nEntities: sulphasalazine, thioguanine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.", "output": "Entities: Thalidomide, barbiturates; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.", "output": "Entities: John's Wort, hormonal contraceptive agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.", "output": "Entities: reserpine, beta-blocking agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.", "output": "Entities: propoxyphene, CNS depressants; Relationship: effect\nEntities: propoxyphene, alcohol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.", "output": "Entities: phenobarbital, montelukast; Relationship: advise\nEntities: rifampin, montelukast; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.", "output": "Entities: phenobarbital, montelukast; Relationship: advise\nEntities: rifampin, montelukast; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).", "output": "Entities: Cimetidine, pramipexole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.", "output": "Entities: cimetidine, pramipexole; Relationship: mechanism\nEntities: ranitidine, pramipexole; Relationship: mechanism\nEntities: diltiazem, pramipexole; Relationship: mechanism\nEntities: triamterene, pramipexole; Relationship: mechanism\nEntities: verapamil, pramipexole; Relationship: mechanism\nEntities: quinidine, pramipexole; Relationship: mechanism\nEntities: quinine, pramipexole; Relationship: mechanism\nEntities: cephalosporins, pramipexole; Relationship: mechanism\nEntities: penicillins, pramipexole; Relationship: mechanism\nEntities: indomethacin, pramipexole; Relationship: mechanism\nEntities: hydrochlorothiazide, pramipexole; Relationship: mechanism\nEntities: chlorpropamide, pramipexole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.", "output": "Entities: dopamine antagonists, MIRAPEX; Relationship: effect\nEntities: neuroleptics, MIRAPEX; Relationship: effect\nEntities: phenothiazines, MIRAPEX; Relationship: effect\nEntities: butyrophenones, MIRAPEX; Relationship: effect\nEntities: thioxanthenes, MIRAPEX; Relationship: effect\nEntities: metoclopramide, MIRAPEX; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.", "output": "Entities: proton pump inhibitors, warfarin; Relationship: effect\nEntities: pantoprazole, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.", "output": "Entities: proton pump inhibitors, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).", "output": "Entities: pantoprazole, ketoconazole; Relationship: mechanism\nEntities: pantoprazole, ampicillin; Relationship: mechanism\nEntities: pantoprazole, iron; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "output": "Entities: acetylcholine chloride, suprofen; Relationship: effect\nEntities: Miochol, suprofen; Relationship: effect\nEntities: carbachol, suprofen; Relationship: effect\nEntities: Carboptic, suprofen; Relationship: effect\nEntities: Isopto Carbachol, suprofen; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.", "output": "Entities: mazindol, monoamine oxidase inhibitor; Relationship: advise\nEntities: mazindol, MAOI; Relationship: advise\nEntities: mazindol, isocarboxazid; Relationship: advise\nEntities: mazindol, Marplan; Relationship: advise\nEntities: mazindol, tranylcypromine; Relationship: advise\nEntities: mazindol, Parnate; Relationship: advise\nEntities: mazindol, phenelzine; Relationship: advise\nEntities: mazindol, Nardil; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.", "output": "Entities: insulin, mazindol; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mazindol may reduce the effects of guanethidine (Ismelin).", "output": "Entities: Mazindol, guanethidine; Relationship: effect\nEntities: Mazindol, Ismelin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.", "output": "Entities: Ethanol, abacavir; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).", "output": "Entities: methadone, ZIAGEN; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.", "output": "Entities: Sulfoxone, barbiturates; Relationship: effect\nEntities: Sulfoxone, tolbutamide; Relationship: effect\nEntities: Sulfoxone, uricosurics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)", "output": "Entities: Phenothiazines, CNS depressants; Relationship: effect\nEntities: Phenothiazines, barbiturates; Relationship: effect\nEntities: Phenothiazines, anesthetics; Relationship: effect\nEntities: Phenothiazines, opiates; Relationship: effect\nEntities: Phenothiazines, alcohol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.", "output": "Entities: megestrol acetate, indinavir; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.", "output": "Entities: indinavir, megestrol acetate; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;", "output": "Entities: Streptozocin, doxorubicin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.", "output": "Entities: doxorubicin, ZANOSAR; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.", "output": "Entities: streptozocin, phenytoin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.", "output": "Entities: digitalis, sympathomimetic amines; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.", "output": "Entities: Monoamine oxidase inhibitors, sympathomimetic amines; Relationship: effect\nEntities: tricyclic antidepressants, sympathomimetic amines; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "output": "Entities: Mequitazine, CNS depressant; Relationship: int\nEntities: Mequitazine, antichlolinergic; Relationship: int\nEntities: Mequitazine, TCA; Relationship: int\nEntities: Mequitazine, MAOIs; Relationship: int\nEntities: Mequitazine, alcohol; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "output": "Entities: Barbiturates, contraceptives; Relationship: int\nEntities: Barbiturates, antibiotics; Relationship: int\nEntities: Barbiturates, quinidine; Relationship: int\nEntities: Barbiturates, theophylline; Relationship: int\nEntities: Barbiturates, corticosteroids; Relationship: int\nEntities: Barbiturates, anticoagulants; Relationship: int\nEntities: Barbiturates, beta blockers; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.", "output": "Entities: Sulfamethizole, barbiturates; Relationship: effect\nEntities: Sulfamethizole, tolbutamide; Relationship: effect\nEntities: Sulfamethizole, uricosurics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.", "output": "Entities: Anticoagulants, TNKase; Relationship: effect\nEntities: heparin, TNKase; Relationship: effect\nEntities: vitamin K antagonists, TNKase; Relationship: effect\nEntities: acetylsalicylic acid, TNKase; Relationship: effect\nEntities: dipyridamole, TNKase; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).", "output": "Entities: rimantadine HCl, Cimetidine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.", "output": "Entities: acetaminophen, rimantadine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.", "output": "Entities: rimantadine, aspirin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Trimethoprim may inhibit the hepatic metabolism of phenytoin.", "output": "Entities: Trimethoprim, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.", "output": "Entities: Trimethoprim, phenytoin; Relationship: mechanism\nEntities: Trimethoprim, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.", "output": "Entities: Pilocarpine, beta adrenergic antagonists; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;", "output": "Entities: cyclosporin, methylprednisolone; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.", "output": "Entities: methylprednisolone, cyclosporin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.", "output": "Entities: phenobarbital, methylprednisolone; Relationship: mechanism\nEntities: phenobarbital, methylprednisolone; Relationship: advise\nEntities: phenytoin, methylprednisolone; Relationship: mechanism\nEntities: phenytoin, methylprednisolone; Relationship: advise\nEntities: rifampin, methylprednisolone; Relationship: mechanism\nEntities: rifampin, methylprednisolone; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.", "output": "Entities: troleandomycin, methylprednisolone; Relationship: mechanism\nEntities: ketoconazole, methylprednisolone; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Methylprednisolone may increase the clearance of chronic high dose aspirin.", "output": "Entities: Methylprednisolone, aspirin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.", "output": "Entities: salicylate, methylprednisolone; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.", "output": "Entities: Aspirin, corticosteroids; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.", "output": "Entities: anticoagulant, corticosteroids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.", "output": "Entities: metoclopramide, anticholinergic drugs; Relationship: effect\nEntities: metoclopramide, narcotic analgesics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.", "output": "Entities: metoclopramide, alcohol; Relationship: effect\nEntities: metoclopramide, sedatives; Relationship: effect\nEntities: metoclopramide, hypnotics; Relationship: effect\nEntities: metoclopramide, narcotics; Relationship: effect\nEntities: metoclopramide, tranquilizers; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.", "output": "Entities: metoclopramide, monoamine oxi-dase inhibitors; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).", "output": "Entities: digoxin, metoclopramide; Relationship: mechanism\nEntities: metoclopramide, acetaminophen; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.", "output": "Entities: metoclopramide, insulin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.", "output": "Entities: Vasopressors, halothane; Relationship: effect\nEntities: metaraminol, halothane; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).", "output": "Entities: sympathomimetic pressor amines, monoamine oxidase inhibitors; Relationship: effect\nEntities: sympathomimetic pressor amines, MAOI; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.", "output": "Entities: adrenergic agents, tricyclic antidepressants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "output": "Entities: Methscopolamine, tricyclic; Relationship: int\nEntities: Methscopolamine, MAO inhibitors; Relationship: int\nEntities: Methscopolamine, phenelzine; Relationship: int\nEntities: Methscopolamine, linezolid; Relationship: int\nEntities: Methscopolamine, tranylcypromine; Relationship: int\nEntities: Methscopolamine, isocarboxazid; Relationship: int\nEntities: Methscopolamine, selegiline; Relationship: int\nEntities: Methscopolamine, furazolidone; Relationship: int\nEntities: Methscopolamine, quinidine; Relationship: int\nEntities: Methscopolamine, amantadine; Relationship: int\nEntities: Methscopolamine, antihistamines; Relationship: int\nEntities: Methscopolamine, diphenhydramine; Relationship: int\nEntities: Methscopolamine, anticholinergics; Relationship: int\nEntities: Methscopolamine, potassium chloride; Relationship: int\nEntities: Methscopolamine, antacids; Relationship: int\nEntities: Methscopolamine, absorbent-type anti-diarrhea medicines; Relationship: int\nEntities: Methscopolamine, kaolin; Relationship: int\nEntities: Methscopolamine, pectin; Relationship: int\nEntities: Methscopolamine, phenothiazines; Relationship: int\nEntities: Methscopolamine, chlorpromazine; Relationship: int\nEntities: Methscopolamine, promethazine; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).", "output": "Entities: SYMLIN, anticholinergic agents; Relationship: advise\nEntities: SYMLIN, atropine; Relationship: advise\nEntities: SYMLIN, alpha glucosidase inhibitors; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.", "output": "Entities: analgesics, SYMLIN; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.", "output": "Entities: SYMLIN, human insulin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.", "output": "Entities: antibiotics, ganglion blockers; Relationship: advise\nEntities: sulfonamides, ganglion blockers; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.", "output": "Entities: Mecamylamine, antihypertensive drugs; Relationship: effect\nEntities: Mecamylamine, alcohol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.", "output": "Entities: metronidazole, coumarin; Relationship: effect\nEntities: metronidazole, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.", "output": "Entities: alcohol, phentermine hydrochloride; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.", "output": "Entities: short-acting beta adrenergic aerosol bronchodilators, MAXAIR AUTOHALER; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.", "output": "Entities: vigabatrin, carbamazepine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.", "output": "Entities: vigabatrin, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.", "output": "Entities: procaine hydrochloride, anticholinesterase agents; Relationship: effect\nEntities: anticholinesterases, procaine hydrochloride; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.", "output": "Entities: procaine hydrochloride, CNS depressant medications; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.", "output": "Entities: Hyaluronidase, procaine hydrochloride; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.", "output": "Entities: procaine hydrochloride, neuromuscular blocking agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.", "output": "Entities: procaine hydrochloride, sulfonamides; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.", "output": "Entities: acetazolamide, procaine hydrochloride; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.", "output": "Entities: SUTENT, ketoconazole; Relationship: mechanism\nEntities: SUTENT, itraconazole; Relationship: mechanism\nEntities: SUTENT, clarithromycin; Relationship: mechanism\nEntities: SUTENT, atazanavir; Relationship: mechanism\nEntities: SUTENT, indinavir; Relationship: mechanism\nEntities: SUTENT, nefazodone; Relationship: mechanism\nEntities: SUTENT, nelfinavir; Relationship: mechanism\nEntities: SUTENT, ritonavir; Relationship: mechanism\nEntities: SUTENT, saquinavir; Relationship: mechanism\nEntities: SUTENT, telithromycin; Relationship: mechanism\nEntities: SUTENT, voriconizole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.", "output": "Entities: SUTENT, dexamethasone; Relationship: mechanism\nEntities: SUTENT, phenytoin; Relationship: mechanism\nEntities: SUTENT, carbamazepine; Relationship: mechanism\nEntities: SUTENT, rifampin; Relationship: mechanism\nEntities: SUTENT, rifabutin; Relationship: mechanism\nEntities: SUTENT, rifapentin; Relationship: mechanism\nEntities: SUTENT, phenobarbital; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "output": "Entities: phenobarbital, corticosteroids; Relationship: mechanism\nEntities: phenobarbital, corticosteroid; Relationship: mechanism\nEntities: phenytoin, corticosteroids; Relationship: mechanism\nEntities: phenytoin, corticosteroid; Relationship: mechanism\nEntities: rifampin, corticosteroids; Relationship: mechanism\nEntities: rifampin, corticosteroid; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "output": "Entities: troleandomycin, corticosteroids; Relationship: mechanism\nEntities: ketoconazole, corticosteroids; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Corticosteroids may increase the clearance of chronic high dose aspirin.", "output": "Entities: Corticosteroids, aspirin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "output": "Entities: salicylate, corticosteroid; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.", "output": "Entities: Aspirin, corticosteroids; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The effect of corticosteroids on oral anticoagulants is variable.", "output": "Entities: corticosteroids, anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.", "output": "Entities: anticoagulants, corticosteroids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "output": "Entities: Vitamin B1, Loop Diuretics; Relationship: int\nEntities: Vitamin B1, Contraceptives; Relationship: int\nEntities: Vitamin B1, Stavudine; Relationship: int\nEntities: Vitamin B1, Tricyclic Antidepressants; Relationship: int\nEntities: Thiamine, Loop Diuretics; Relationship: int\nEntities: Thiamine, Contraceptives; Relationship: int\nEntities: Thiamine, Stavudine; Relationship: int\nEntities: Thiamine, Tricyclic Antidepressants; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.", "output": "Entities: cholinesterase inhibitors, anticholinergic medications; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "output": "Entities: cholinesterase inhibitors, succinylcholine; Relationship: effect\nEntities: cholinesterase inhibitors, neuromuscular blocking agents; Relationship: effect\nEntities: cholinesterase inhibitors, cholinergic agonists; Relationship: effect\nEntities: cholinesterase inhibitors, bethanechol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.", "output": "Entities: ketoconazole, terfenadine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.", "output": "Entities: ketoconazole, terfenadine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of ketoconazole and terfenadine is contraindicated.", "output": "Entities: ketoconazole, terfenadine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.", "output": "Entities: terfenadine, itraconazole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of itraconazole and terfenadine is contraindicated.", "output": "Entities: itraconazole, terfenadine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.", "output": "Entities: azole-type antifungal agents, terfenadine; Relationship: advise\nEntities: fluconazole, terfenadine; Relationship: advise\nEntities: metronidazole, terfenadine; Relationship: advise\nEntities: miconazole, terfenadine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.", "output": "Entities: erythromycin, terfenadine; Relationship: mechanism\nEntities: clarithromycin, terfenadine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.", "output": "Entities: terfenadine, clarithromycin; Relationship: advise\nEntities: terfenadine, erythromycin; Relationship: advise\nEntities: terfenadine, troleandomycin; Relationship: advise\nEntities: terfenadine, macrolide antibiotics; Relationship: advise\nEntities: terfenadine, azithromycin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).", "output": "Entities: NEXAVAR, irinotecan; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.", "output": "Entities: NEXAVAR, doxorubicin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution is recommended when administering doxorubicin with NEXAVAR.", "output": "Entities: doxorubicin, NEXAVAR; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;", "output": "Entities: methadone, PEG-Intron; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.", "output": "Entities: mexiletine, fluvoxamine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.", "output": "Entities: phenytoin, Mexitil; Relationship: mechanism\nEntities: rifampin, Mexitil; Relationship: mechanism\nEntities: phenobarbital, Mexitil; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;", "output": "Entities: cimetidine, Mexitil; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.", "output": "Entities: magnesium-aluminum hydroxide, digoxin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.", "output": "Entities: Mexitil, theophylline; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.", "output": "Entities: Theophylline, Mexitil; Relationship: mechanism\nEntities: Mexitil, theophylline; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .", "output": "Entities: caffeine, Mexitil; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.", "output": "Entities: alcohol, pentazocine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.", "output": "Entities: Thiabendazole, theophylline; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.", "output": "Entities: thiabendazole, xanthine derivatives; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.", "output": "Entities: lorazepam, pyrimethamine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.", "output": "Entities: Posicor, terfenadine; Relationship: mechanism\nEntities: Posicor, astemizole; Relationship: mechanism\nEntities: Posicor, cisapride; Relationship: mechanism\nEntities: Posicor, cyclosporine; Relationship: mechanism\nEntities: Posicor, tricyclic antidepressants; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).", "output": "Entities: Trilostane, aminoglutethimide; Relationship: int\nEntities: Trilostane, mitotane; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.", "output": "Entities: probenecid, ALIMTA; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).", "output": "Entities: ibuprofen, ALIMTA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.", "output": "Entities: NSAIDs, ALIMTA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.", "output": "Entities: NSAIDs, ALIMTA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Ritalin may decrease the hypotensive effect of guanethidine.", "output": "Entities: Ritalin, guanethidine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).", "output": "Entities: Ritalin, coumarin anticoagulants; Relationship: mechanism\nEntities: Ritalin, anticonvulsants; Relationship: mechanism\nEntities: Ritalin, phenobarbital; Relationship: mechanism\nEntities: Ritalin, diphenylhydantoin; Relationship: mechanism\nEntities: Ritalin, primidone; Relationship: mechanism\nEntities: Ritalin, phenylbutazone; Relationship: mechanism\nEntities: Ritalin, tricyclic drugs; Relationship: mechanism\nEntities: Ritalin, imipramine; Relationship: mechanism\nEntities: Ritalin, clomipramine; Relationship: mechanism\nEntities: Ritalin, desipramine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.", "output": "Entities: ZOLINZA, coumarin-derivative anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.", "output": "Entities: ZOLINZA, coumarin derivatives; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).", "output": "Entities: ZOLINZA, HDAC inhibitors; Relationship: effect\nEntities: ZOLINZA, valproic acid; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.", "output": "Entities: 5-FU, ELOXATIN; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.", "output": "Entities: XENICAL, cyclosporine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.", "output": "Entities: beta-carotene, XENICAL; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.", "output": "Entities: XENICAL, vitamin E acetate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "output": "Entities: vitamin K, XENICAL; Relationship: mechanism\nEntities: warfarin, XENICAL; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Terbinafine decreases the clearance of caffeine by 19%.", "output": "Entities: Terbinafine, caffeine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Terbinafine increases the clearance of cyclosporine by 15%.", "output": "Entities: Terbinafine, cyclosporine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.", "output": "Entities: terbinafine, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.", "output": "Entities: Terbinafine, rifampin; Relationship: mechanism\nEntities: Terbinafine, cimetidine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.", "output": "Entities: ASPIRIN, DISALCID; Relationship: effect\nEntities: SALICYLATE DRUGS, DISALCID; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.", "output": "Entities: Salicylates, anticoagulant drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.", "output": "Entities: Salicylates, antidiabetic drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.", "output": "Entities: Salicylate, penicillin; Relationship: mechanism\nEntities: Salicylate, thiopental; Relationship: mechanism\nEntities: Salicylate, thyroxine; Relationship: mechanism\nEntities: Salicylate, triiodothyronine; Relationship: mechanism\nEntities: Salicylate, phenytoin; Relationship: mechanism\nEntities: Salicylate, sulfinpyrazone; Relationship: mechanism\nEntities: Salicylate, naproxen; Relationship: mechanism\nEntities: Salicylate, warfarin; Relationship: mechanism\nEntities: Salicylate, methotrexate; Relationship: mechanism\nEntities: Salicylate, corticosteroids; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.", "output": "Entities: reserpine, beta-blocking agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.", "output": "Entities: Pindolol, thioridazine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).", "output": "Entities: ketoconazole, mifepristone; Relationship: mechanism\nEntities: itraconazole, mifepristone; Relationship: mechanism\nEntities: erythromycin, mifepristone; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).", "output": "Entities: anticonvulsants, mifepristone; Relationship: mechanism\nEntities: phenytoin, mifepristone; Relationship: mechanism\nEntities: phenobarbital, mifepristone; Relationship: mechanism\nEntities: carbamazepine, mifepristone; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.", "output": "Entities: heparin, Retavase; Relationship: effect\nEntities: vitamin K antagonists, Retavase; Relationship: effect\nEntities: aspirin, Retavase; Relationship: effect\nEntities: dipyridamole, Retavase; Relationship: effect\nEntities: abciximab, Retavase; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.", "output": "Entities: selegiline, meperidine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This is typical of the interaction of meperidine and MAOIs.", "output": "Entities: meperidine, MAOIs; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.", "output": "Entities: tricyclic antidepressants, ELDEPRYL; Relationship: effect\nEntities: selective serotonin reuptake inhibitors, ELDEPRYL; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).", "output": "Entities: selegiline, sympathomimetic medication; Relationship: effect\nEntities: selegiline, ephedrine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.", "output": "Entities: ZADAXIN, immunomodulating drugs; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.", "output": "Entities: DEMSER, phenothiazines; Relationship: advise\nEntities: DEMSER, haloperidol; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "output": "Entities: DEMSER, alcohol; Relationship: effect\nEntities: DEMSER, CNS depressants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The metabolism of Metopirone is accelerated by phenytoin;", "output": "Entities: Metopirone, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.", "output": "Entities: Metopirone, acetaminophen; Relationship: mechanism\nEntities: Metopirone, acetaminophen; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);", "output": "Entities: Dopamine antagonists, Permax; Relationship: advise\nEntities: neuroleptics, Permax; Relationship: advise\nEntities: phenothiazines, Permax; Relationship: advise\nEntities: butyrophenones, Permax; Relationship: advise\nEntities: thioxanthines, Permax; Relationship: advise\nEntities: metoclopramide, Permax; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.", "output": "Entities: ketoconazole, retapamulin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.", "output": "Entities: ketoconazole, paricalcitol; Relationship: mechanism\nEntities: paricalcitol, ketoconazole; Relationship: advise\nEntities: paricalcitol, atazanavir; Relationship: advise\nEntities: paricalcitol, clarithromycin; Relationship: advise\nEntities: paricalcitol, indinavir; Relationship: advise\nEntities: paricalcitol, itraconazole; Relationship: advise\nEntities: paricalcitol, nefazodone; Relationship: advise\nEntities: paricalcitol, nelfinavir; Relationship: advise\nEntities: paricalcitol, ritonavir; Relationship: advise\nEntities: paricalcitol, saquinavir; Relationship: advise\nEntities: paricalcitol, telithromycin; Relationship: advise\nEntities: paricalcitol, voriconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.", "output": "Entities: Zemplar, ketoconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.", "output": "Entities: fat-soluble vitamins, cholestyramine; Relationship: mechanism\nEntities: cholestyramine, Zemplar; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "output": "Entities: aspirin, methazolamide; Relationship: advise\nEntities: aspirin, carbonic anhydrase inhibitors; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.", "output": "Entities: FLOMAX, alpha-adrenergic blocking agents; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.", "output": "Entities: FLOMAX, cimetidine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.", "output": "Entities: warfarin, FLOMAX; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.", "output": "Entities: GH, antipyrine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).", "output": "Entities: GH, corticosteroids; Relationship: mechanism\nEntities: GH, sex steroids; Relationship: mechanism\nEntities: GH, anticonvulsants; Relationship: mechanism\nEntities: GH, cyclosporin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..", "output": "Entities: oxycodone hydrochloride, CNS depressants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.", "output": "Entities: morphine, CNS depressants; Relationship: effect\nEntities: morphine, alcohol; Relationship: effect\nEntities: morphine, sedatives; Relationship: effect\nEntities: morphine, antihistaminics; Relationship: effect\nEntities: morphine, psychotropic drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.", "output": "Entities: neuroleptics, morphine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.", "output": "Entities: Agonist/antagonist analgesics, opioid agonist analgesic; Relationship: advise\nEntities: pentazocine, opioid agonist analgesic; Relationship: advise\nEntities: nalbuphine, opioid agonist analgesic; Relationship: advise\nEntities: butorphanol, opioid agonist analgesic; Relationship: advise\nEntities: buprenorphine, opioid agonist analgesic; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.", "output": "Entities: ergotamine, sumatriptan; Relationship: advise\nEntities: ergot-type medications, sumatriptan; Relationship: advise\nEntities: dihydroergotamine, sumatriptan; Relationship: advise\nEntities: methysergide, sumatriptan; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.", "output": "Entities: MAO-A inhibitors, sumatriptan; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.", "output": "Entities: sumatriptan succinate, MAO-A inhibitors; Relationship: advise\nEntities: Selective serotonin reuptake inhibitors, sumatriptan; Relationship: effect\nEntities: SSRIs, sumatriptan; Relationship: effect\nEntities: fluoxetine, sumatriptan; Relationship: effect\nEntities: fluvoxamine, sumatriptan; Relationship: effect\nEntities: paroxetine, sumatriptan; Relationship: effect\nEntities: sertraline, sumatriptan; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "output": "Entities: sumatriptan, SSRI; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.", "output": "Entities: Myfortic, magnesium; Relationship: mechanism\nEntities: Myfortic, aluminum; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It is recommended that Myfortic and antacids not be administered simultaneously.", "output": "Entities: Myfortic, antacids; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.", "output": "Entities: Myfortic, azathioprine; Relationship: advise\nEntities: Myfortic, mycophenolate mofetil; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.", "output": "Entities: Myfortic, cholestyramine; Relationship: advise\nEntities: Myfortic, activated charcoal; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.", "output": "Entities: levonorgesterol, mycophenolate mofetil; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.", "output": "Entities: contraceptives, Myfortic; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.", "output": "Entities: Myfortic, live attenuated vaccines; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.", "output": "Entities: coumarin-type anticoagulants, FELDENE; Relationship: int\nEntities: FELDENE, coumarin-type anticoagulants; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.", "output": "Entities: FELDENE, aspirin; Relationship: mechanism\nEntities: Nonsteroidal anti-inflammatory agents, lithium; Relationship: mechanism\nEntities: FELDENE, lithium; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.", "output": "Entities: lithium, FELDENE; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.", "output": "Entities: Vasopressors, halothane; Relationship: effect\nEntities: metaraminol, halothane; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).", "output": "Entities: sympathomimetic pressor amines, monoamine oxidase inhibitors; Relationship: effect\nEntities: sympathomimetic pressor amines, MAOI; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.", "output": "Entities: adrenergic agents, tricyclic antidepressants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.", "output": "Entities: insulin, SOMAVERT; Relationship: advise\nEntities: hypoglycemic, SOMAVERT; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.", "output": "Entities: opioids, pegvisomant; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.", "output": "Entities: digoxin, sitagliptin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.", "output": "Entities: ascorbic acid, bishydroxycoumarin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "output": "Entities: Vindesine, Phenytoin; Relationship: int\nEntities: Vindesine, Live virus vaccines; Relationship: int\nEntities: Vindesine, Mitomycin-C; Relationship: int\nEntities: Vindesine, Killed virus vaccines; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.", "output": "Entities: potassium-sparing diuretics, ACE inhibitors; Relationship: effect\nEntities: spironolactone, ACE inhibitors; Relationship: effect\nEntities: triamterene, ACE inhibitors; Relationship: effect\nEntities: amiloride, ACE inhibitors; Relationship: effect\nEntities: potassium, ACE inhibitors; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "output": "Entities: ACE inhibitors, lithium; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If a diuretic is also used, the risk of lithium toxicity may be increased.", "output": "Entities: diuretic, lithium; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "output": "Entities: Melatonin, aspirin; Relationship: int\nEntities: Melatonin, NSAIDs; Relationship: int\nEntities: Melatonin, fluvoxamine; Relationship: int\nEntities: Melatonin, beta blockers; Relationship: int\nEntities: Melatonin, fluoxetine; Relationship: int\nEntities: Melatonin, progestin; Relationship: int\nEntities: Melatonin, benzodiazepenes; Relationship: int\nEntities: Melatonin, corticosteroids; Relationship: int\nEntities: melatonin, progestin; Relationship: effect\nEntities: melatonin, corticosteroids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.", "output": "Entities: alcohol, mirtazapine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.", "output": "Entities: REMERON, alcohol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.", "output": "Entities: alcohol, REMERON SolTab; Relationship: advise\nEntities: diazepam, mirtazapine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.", "output": "Entities: REMERON, diazepam; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.", "output": "Entities: diazepam, REMERON SolTab; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).", "output": "Entities: MEPERIDINE, NARCOTIC ANALGESICS; Relationship: advise\nEntities: MEPERIDINE, ANESTHETICS; Relationship: advise\nEntities: MEPERIDINE, PHENOTHIAZINES; Relationship: advise\nEntities: MEPERIDINE, TRANQUILIZERS; Relationship: advise\nEntities: MEPERIDINE, SEDATIVE-HYPNOTICS; Relationship: advise\nEntities: MEPERIDINE, BARBITURATES; Relationship: advise\nEntities: MEPERIDINE, TRICYCLIC ANTIDEPRESSANTS; Relationship: advise\nEntities: MEPERIDINE, CNS DEPRESSANTS; Relationship: advise\nEntities: MEPERIDINE, ALCOHOL; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.", "output": "Entities: bacteriostatic antibiotics, penicillins; Relationship: effect\nEntities: erythromycin, penicillins; Relationship: effect\nEntities: tetracycline, penicillins; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.", "output": "Entities: Penicillin, probenecid; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.", "output": "Entities: contraceptives, vitamin A; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.", "output": "Entities: CHEMET, CaNa 2 EDTA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.", "output": "Entities: methyldopa, antihypertensive drugs; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients may require reduced doses of anesthetics when on methyldopa.", "output": "Entities: anesthetics, methyldopa; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.", "output": "Entities: methyldopa, lithium; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.", "output": "Entities: methyldopa, ferrous sulfate; Relationship: mechanism\nEntities: methyldopa, ferrous gluconate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.", "output": "Entities: methyldopa, ferrous sulfate; Relationship: advise\nEntities: methyldopa, ferrous gluconate; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.", "output": "Entities: norepinephrine, sodium bicarbonate; Relationship: int\nEntities: dobutamine, sodium bicarbonate; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.", "output": "Entities: SKELID, calcium; Relationship: mechanism\nEntities: aluminum, SKELID; Relationship: mechanism\nEntities: magnesium, SKELID; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.", "output": "Entities: Aspirin, SKELID; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.", "output": "Entities: SKELID, indomethacin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "output": "Entities: Tetracycline, penicillin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.", "output": "Entities: Scopolamine, sedatives; Relationship: advise\nEntities: Scopolamine, tranquilizers; Relationship: advise\nEntities: Scopolamine, alcohol; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)", "output": "Entities: DIPRIVAN, narcotics; Relationship: effect\nEntities: DIPRIVAN, morphine; Relationship: effect\nEntities: DIPRIVAN, meperidine; Relationship: effect\nEntities: DIPRIVAN, fentanyl; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).", "output": "Entities: DIPRIVAN, analgesic agents; Relationship: advise\nEntities: DIPRIVAN, nitrous oxide; Relationship: advise\nEntities: DIPRIVAN, opioids; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.", "output": "Entities: TOLECTIN, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.", "output": "Entities: TOLECTIN, anticoagulants; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be used if TOLECTIN is administered concomitantly with methotrexate.", "output": "Entities: TOLECTIN, methotrexate; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.", "output": "Entities: TOLECTIN, methotrexate; Relationship: mechanism\nEntities: nonsteroidal anti-inflammatory drugs, methotrexate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.", "output": "Entities: Thiazide diuretics, phenothiazines; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.", "output": "Entities: guanethidine, phenothiazines; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.", "output": "Entities: propranolol, phenothiazines; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.", "output": "Entities: TOBI, dornase alfa; Relationship: effect\nEntities: TOBI, PULMOZYME; Relationship: effect\nEntities: TOBI, (beta)-agonists; Relationship: effect\nEntities: TOBI, corticosteroids; Relationship: effect\nEntities: TOBI, anti-pseudomonal antibiotics; Relationship: effect\nEntities: TOBI, aminoglycosides; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.", "output": "Entities: diuretics, aminoglycoside; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.", "output": "Entities: TOBI, ethacrynic acid; Relationship: advise\nEntities: TOBI, furosemide; Relationship: advise\nEntities: TOBI, urea; Relationship: advise\nEntities: TOBI, mannitol; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.", "output": "Entities: gemfibrozil, rosiglitazone; Relationship: mechanism\nEntities: rifampin, rosiglitazone; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.", "output": "Entities: Cholestyramine, raloxifene; Relationship: mechanism\nEntities: Cholestyramine, EVISTA; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.", "output": "Entities: EVISTA, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.", "output": "Entities: EVISTA, clofibrate; Relationship: advise\nEntities: EVISTA, indomethacin; Relationship: advise\nEntities: EVISTA, naproxen; Relationship: advise\nEntities: EVISTA, ibuprofen; Relationship: advise\nEntities: EVISTA, diazepam; Relationship: advise\nEntities: EVISTA, diazoxide; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.", "output": "Entities: Probenecid, meropenem; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, the coadministration of probenecid with meropenem is not recommended.", "output": "Entities: probenecid, meropenem; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).", "output": "Entities: meropenem, valproic acid; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.", "output": "Entities: beta adrenergic aerosol bronchodilators, Alupent; Relationship: advise\nEntities: beta adrenergic aerosol bronchodilators, metaproterenol sulfate; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.", "output": "Entities: Beta adrenergic agonists, monoamine oxidase inhibitors; Relationship: advise\nEntities: Beta adrenergic agonists, tricyclic antidepressants; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.", "output": "Entities: ZEMURON, succinylcholine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.", "output": "Entities: phenytoin, ondansetron; Relationship: mechanism\nEntities: phenytoin, ondansetron; Relationship: mechanism\nEntities: carbamazepine, ondansetron; Relationship: mechanism\nEntities: carbamazepine, ondansetron; Relationship: mechanism\nEntities: rifampicin, ondansetron; Relationship: mechanism\nEntities: rifampicin, ondansetron; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.", "output": "Entities: ondansetron, tramadol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.", "output": "Entities: paclitaxel, HERCEPTIN; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.", "output": "Entities: macrolides, terfenadine; Relationship: int\nEntities: macrolides, astemizole; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.", "output": "Entities: roxithromycin, terfenadine; Relationship: advise\nEntities: roxithromycin, astemizole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.", "output": "Entities: pimozide, macrolide antibacterials; Relationship: mechanism\nEntities: cisapride, macrolide antibacterials; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Some anticonvulsants may interact with Mephenytoin.", "output": "Entities: anticonvulsants, Mephenytoin; Relationship: int"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "output": "Entities: Mephenytoin, steroid medications; Relationship: effect\nEntities: Mephenytoin, warfarin; Relationship: effect\nEntities: Mephenytoin, anti-infective medicines; Relationship: effect\nEntities: Mephenytoin, furosemide; Relationship: effect\nEntities: Mephenytoin, theophylline; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.", "output": "Entities: Streptase, antiplatelet agents; Relationship: effect\nEntities: Streptase, anticoagulants; Relationship: effect\nEntities: Streptokinase, antiplatelet agents; Relationship: effect\nEntities: Streptokinase, anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see", "output": "Entities: aspirin, Streptokinase; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.", "output": "Entities: MAO inhibitors, pseudoephedrine; Relationship: effect\nEntities: beta adrenergic blockers, pseudoephedrine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "output": "Entities: Sympathomimetics, methyldopa; Relationship: effect\nEntities: Sympathomimetics, mecamylamine; Relationship: effect\nEntities: Sympathomimetics, reserpine; Relationship: effect\nEntities: Sympathomimetics, veratrum alkaloids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "output": "Entities: tetracyclines, anticoagulant; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.", "output": "Entities: tetracycline class drugs, penicillin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.", "output": "Entities: tetracyclines, aluminum; Relationship: mechanism\nEntities: tetracyclines, calcium; Relationship: mechanism\nEntities: tetracyclines, magnesium; Relationship: mechanism\nEntities: tetracyclines, iron; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.", "output": "Entities: tetracycline, methoxyflurane; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "output": "Entities: tetracyclines, contraceptives; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.", "output": "Entities: Sanctura, anticholinergic agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).", "output": "Entities: Sanctura, digoxin; Relationship: mechanism\nEntities: Sanctura, procainamide; Relationship: mechanism\nEntities: Sanctura, pancuronium; Relationship: mechanism\nEntities: Sanctura, morphine; Relationship: mechanism\nEntities: Sanctura, vancomycin; Relationship: mechanism\nEntities: Sanctura, metformin; Relationship: mechanism\nEntities: Sanctura, tenofovir; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.", "output": "Entities: Nalidixic acid, melphalan; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease", "output": "Entities: melphalan, cyclosporin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).", "output": "Entities: midazolam, azole antimycotics; Relationship: advise\nEntities: midazolam, protease inhibitors; Relationship: advise\nEntities: midazolam, calcium channel antagonists; Relationship: advise\nEntities: midazolam, macrolide antibiotics; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.", "output": "Entities: erythromycin, midazolam; Relationship: mechanism\nEntities: diltiazem, midazolam; Relationship: mechanism\nEntities: verapamil, midazolam; Relationship: mechanism\nEntities: ketoconazole, midazolam; Relationship: mechanism\nEntities: fluconazole, midazolam; Relationship: mechanism\nEntities: itraconazole, midazolam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.", "output": "Entities: ritonavir, midazolam; Relationship: mechanism\nEntities: nelfinavir, midazolam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.", "output": "Entities: rifampin, midazolam; Relationship: mechanism\nEntities: carbamazepine, midazolam; Relationship: mechanism\nEntities: phenytoin, midazolam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.", "output": "Entities: VERSED Syrup, narcotics; Relationship: effect\nEntities: VERSED Syrup, morphine; Relationship: effect\nEntities: VERSED Syrup, meperidine; Relationship: effect\nEntities: VERSED Syrup, fentanyl; Relationship: effect\nEntities: VERSED Syrup, propofol; Relationship: effect\nEntities: VERSED Syrup, ketamine; Relationship: effect\nEntities: VERSED Syrup, nitrous oxide; Relationship: effect\nEntities: VERSED Syrup, secobarbital; Relationship: effect\nEntities: VERSED Syrup, droperidol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.", "output": "Entities: Leukine, lithium; Relationship: effect\nEntities: Leukine, corticosteroids; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;", "output": "Entities: DIFLUCAN, hypoglycemic agents; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.", "output": "Entities: DIFLUCAN, glyburide; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.", "output": "Entities: DIFLUCAN, tolbutamide; Relationship: mechanism\nEntities: DIFLUCAN, glyburide; Relationship: mechanism\nEntities: DIFLUCAN, glipizide; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.", "output": "Entities: DIFLUCAN, sulfonylurea oral hypoglycemic agents; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.", "output": "Entities: DIFLUCAN, coumarin-type anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.", "output": "Entities: fluconazole, warfarin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.", "output": "Entities: DIFLUCAN, coumarin-type anticoagulants; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.", "output": "Entities: DIFLUCAN, phenytoin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.", "output": "Entities: DIFLUCAN, phenytoin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.", "output": "Entities: DIFLUCAN, cyclosporine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.", "output": "Entities: DIFLUCAN, cyclosporine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.", "output": "Entities: Rifampin, DIFLUCAN; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.", "output": "Entities: DIFLUCAN, rifampin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Theophylline: DIFLUCAN increases the serum concentrations of theophylline.", "output": "Entities: DIFLUCAN, theophylline; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.", "output": "Entities: DIFLUCAN, theophylline; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.", "output": "Entities: azole antifungals, terfenadine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.", "output": "Entities: DIFLUCAN, terfenadine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.", "output": "Entities: fluconazole, terfenadine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.", "output": "Entities: fluconazole, terfenadine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.", "output": "Entities: fluconazole, cisapride; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.", "output": "Entities: fluconazole, cisapride; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The combined use of fluconazole with cisapride is contraindicated.", "output": "Entities: fluconazole, cisapride; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.", "output": "Entities: fluconazole, astemizole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.", "output": "Entities: fluconazole, rifabutin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.", "output": "Entities: rifabutin, fluconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.", "output": "Entities: fluconazole, tacrolimus; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.", "output": "Entities: tacrolimus, fluconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.", "output": "Entities: midazolam, fluconazole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.", "output": "Entities: midazolam, fluconazole; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.", "output": "Entities: short-acting benzodiazepines, fluconazole; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;", "output": "Entities: Fluconazole, ethinyl estradiol; Relationship: mechanism\nEntities: Fluconazole, levonorgestrel; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.", "output": "Entities: fluconazole, ethinyl estradiol; Relationship: mechanism\nEntities: fluconazole, levonorgestrel; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.", "output": "Entities: TRENTAL, anticoagulants; Relationship: effect\nEntities: TRENTAL, platelet aggregation inhibitors; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.", "output": "Entities: TRENTAL, theophylline; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.", "output": "Entities: NSAIDs, angiotensin-converting enzyme (ACE) inhibitors; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.", "output": "Entities: NSAIDs, ACE inhibitors; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.", "output": "Entities: aspirin, meloxicam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.", "output": "Entities: NSAIDs, aspirin; Relationship: advise\nEntities: meloxicam, aspirin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.", "output": "Entities: aspirin, MOBIC; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.", "output": "Entities: cholestyramine, meloxicam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.", "output": "Entities: NSAIDs, furosemide; Relationship: effect\nEntities: NSAIDs, thiazide diuretics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.", "output": "Entities: furosemide, MOBIC; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "output": "Entities: NSAIDs, lithium; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.", "output": "Entities: lithium, meloxicam; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.", "output": "Entities: lithium, MOBIC; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.", "output": "Entities: MOBIC, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.", "output": "Entities: MOBIC, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.", "output": "Entities: ProAmatine, cardiac glycosides; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.", "output": "Entities: phenylephrine, ProAmatine; Relationship: effect\nEntities: pseudoephedrine, ProAmatine; Relationship: effect\nEntities: ephedrine, ProAmatine; Relationship: effect\nEntities: phenylpropanolamine, ProAmatine; Relationship: effect\nEntities: dihydroergotamine, ProAmatine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.", "output": "Entities: Alpha-adrenergic blocking agents, ProAmatine; Relationship: effect\nEntities: prazosin, ProAmatine; Relationship: effect\nEntities: terazosin, ProAmatine; Relationship: effect\nEntities: doxazosin, ProAmatine; Relationship: effect\nEntities: desglymidodrine, metformin; Relationship: mechanism\nEntities: desglymidodrine, cimetidine; Relationship: mechanism\nEntities: desglymidodrine, ranitidine; Relationship: mechanism\nEntities: desglymidodrine, procainamide; Relationship: mechanism\nEntities: desglymidodrine, triamterene; Relationship: mechanism\nEntities: desglymidodrine, flecainide; Relationship: mechanism\nEntities: desglymidodrine, quinidine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.", "output": "Entities: cimetidine, mebendazole; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin", "output": "Entities: Alcohol, riboflavin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;", "output": "Entities: Probenecid, riboflavin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "requirements for riboflavin may be increased in patients receiving probenecid.", "output": "Entities: riboflavin, probenecid; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.", "output": "Entities: Anticholinergics, opioid analgesics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.", "output": "Entities: oxymorphone, propofol; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;", "output": "Entities: cimetidine, opioid analgesics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "output": "Entities: Celontin, antiepileptic drugs; Relationship: advise\nEntities: methsuximide, antiepileptic drugs; Relationship: advise\nEntities: methsuximide, phenytoin; Relationship: mechanism\nEntities: methsuximide, phenobarbital; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.", "output": "Entities: atropine, pralidoxime; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;", "output": "Entities: barbiturates, anticholinesterases; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.", "output": "Entities: folic acid, sulfasalazine; Relationship: mechanism\nEntities: digoxin, sulfasalazine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.", "output": "Entities: Anabolic steroids, anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.", "output": "Entities: oxandrolone, warfarin; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.", "output": "Entities: oxandrolone, warfarin; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.", "output": "Entities: warfarin, oxandrolone; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.", "output": "Entities: Oxandrolone, hypoglycemic agents; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Methysergide may reverse the analgesic activity of narcotic analgesics.", "output": "Entities: Methysergide, narcotic analgesics; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.", "output": "Entities: Zidovudine, stavudine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Therefore, use of zidovudine in combination with ZERIT should be avoided.", "output": "Entities: zidovudine, ZERIT; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.", "output": "Entities: stavudine, doxorubicin; Relationship: effect\nEntities: stavudine, ribavirin; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "When administered concurrently, testolactone may increase the effects of oral anticoagulants;", "output": "Entities: testolactone, anticoagulants; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.", "output": "Entities: cholestyramine, ezetimibe; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.", "output": "Entities: ezetimibe, cholestyramine; Relationship: effect"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.", "output": "Entities: ZETIA, fibrates; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.", "output": "Entities: fenofibrate, ezetimibe; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.", "output": "Entities: ezetimibe, cyclosporine; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "Patients who take both ezetimibe and cyclosporine should be carefully monitored.", "output": "Entities: ezetimibe, cyclosporine; Relationship: advise"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.", "output": "Entities: ketoconazole, mometasone furoate; Relationship: mechanism"}
{"instruction": "Extract drug entities and their relationships from the following biomedical text.", "input": "SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.", "output": "Entities: SKELAXIN, alcohol; Relationship: effect\nEntities: SKELAXIN, barbiturates; Relationship: effect\nEntities: SKELAXIN, CNS depressants; Relationship: effect"}
